Half dose sugammadex combined with neostigmine is non-inferior to full dose sugammadex for reversal of rocuronium-induced deep neuromuscular blockade: a cost-saving strategy

Table 2 Characteristics of neuromuscular block recovery

	Group S (n = 28)	Group NS (n = 28)	Difference	95% confidence interval of the difference
Number of patients with TOF 0.9 within 5 min (intention-to-treat analysis)	27 (96)	25 (89)	7%	−9% to 24%
Number of patients with TOF 0.9 within 5 min (per-protocol analysis)^a	26 (100)	23 (92)	8%	−6% to 25%
Time to TOF 0.9 (sec)	180.9 ± 96.8	228.2 ± 83.9	−47.32	−95.9 to 1.2
TOF ratio at 5 min	0.96 ± 0.11	0.94 ± 0.07	0.02	−0.03 to 0.07
Time to extubation (sec)	502.5 ± 192.0	532.1 ± 167.1	−29.6	−126.0 to 66.8
Vials of sugammadex used per patient	2 ± 0.5	1.2 ± 0.4	0.82	0.59 to 1.1

The primary outcome was tested for non-inferiority and expressed as numbers (%) and confidence intervals for the difference of percentages. The non-inferiority margin delta was set at 10%. Non-inferiority was met since the lower limit of a 2-sided 95% confidence interval is less than 10%. Secondary outcomes were expressed as means ± SD and analyzed using Student t test
S Sugammadex, NS Neostigmine and Sugammadex, TOF Train of Four
^aPer-protocol analysis: n = 26 in group S and n = 25 in group NS

ISSN: 1471-2253